Could a daily serving of grapes alter your gut bacteria and immune defenses?

NCT ID NCT07797803

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

Researchers are testing whether eating grape powder every day for four weeks changes the types of bacteria in the gut and markers of immune activity in healthy adults aged 45 to 65. Participants will be randomly assigned to receive either grape powder or a placebo, and provide stool and blood samples before, during, and after the intervention. The study uses advanced DNA sequencing and metabolite analysis to look for shifts in beneficial or harmful bacteria and related immune signals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Grape powder (72 g daily for 28 days) compared with a placebo powder
What this could lead to
If it works, this could point toward a simple dietary way to support gut health and immune function in healthy adults.
What could go wrong
This is a small, early-stage trial with only 40 participants, so results may not apply broadly. The effect on gut bacteria may be modest or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Healthy adults between the ages of 45 and 65 years old * Body Mass Index (BMI) within the range of 18.5 to 25.9 kg/m² * Willing and able to provide informed consent * Agreement to maintain usual dietary patterns throughout the study, except for the provided study powder * Agreement to avoid exclusion criteria (below) during the study period * Able and willing to collect and mail a stool sample during the microbiome screening phase and, if enrolled in the intervention phase, and at the three defined study timepoints * For enrollment into the intervention phase, meeting pre-specified microbiome eligibility criteria based on the screening stool sample, as defined in the study protocol. Exclusion Criteria * Antibiotic use within 6 months prior to enrollment, or any planned antibiotic use during the study * Recent initiation of or dose change in any medication or supplement within 3 months prior to enrollment, or planned initiation or dose change during the study * Initiation or change of probiotic, prebiotic, or synbiotic supplements during the study. Existing long-term stable probiotic use is permitted * Current or recent (within 3 months) systemic corticosteroid, biologic, DMARD, chemotherapy, or other immunosuppressive therapy; regular NSAID use (more than 2 doses per week); or planned initiation of any of the above during the study * Active inflammatory bowel disease, irritable bowel syndrome with current symptoms, celiac disease, microscopic colitis, active diverticulitis, or acute gastrointestinal infection within 3 months; any history of C. difficile infection; or prior bariatric surgery or bowel resection * Uncontrolled or unstable chronic disease, including but not limited to uncontrolled diabetes (HbA1c \>8%), chronic hepatitis B or C, cirrhosis, moderate-to-severe chronic kidney disease (eGFR \<60), active or recent (within 5 years) malignancy, solid organ or bone marrow transplant, or uncontrolled cardiovascular or psychiatric illness * Planned major change in diet, physical activity, or lifestyle during the study period; recent significant weight change (\>5% in 3 months); or current adherence to an extreme dietary pattern (strict vegan, ketogenic, carnivore, or very-low-carb) maintained for more than 3 months * Habitual high polyphenol intake, including daily consumption of more than 2 servings of berries, more than 500 mL of red wine, more than 4 cups of tea, or regular consumption of pomegranate, grape juice, or dark chocolate more than 3 times per week, as assessed by screening food-frequency questionnaire * Heavy alcohol use (more than 14 drinks per week), current tobacco use, or daily cannabis use * Known grape allergy or sensitivity; pregnancy, planned pregnancy, or breastfeeding during the study; current participation in other interventional clinical trials; or any condition that, in the investigator's judgment, would compromise study participation, compliance, or data interpretation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gut microbiomes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.